The SLC16A11 risk haplotype is associated with decreased insulin action, higher transaminases and large-size adipocytes.
Almeda-Valdes P, Gómez Velasco DV, Arellano Campos O, Bello-Chavolla OY, Del Rocío Sevilla-González M, Viveros Ruiz T, Martagón Rosado AJ, Bautista CJ, Muñoz Hernandez L, Cruz-Bautista I, Moreno-Macias H, Huerta-Chagoya A, Rodríguez-Álvarez KG, Walford GA, Jacobs SBR, Guillen Pineda LE, Ordoñez-Sánchez ML, Roldan-Valadez E, Azpiroz J, Furuzawa-Carballeda J, Clark P, Herrera-Hernández MF, Zambrano E, Florez JC, Tusié Luna MT, Aguilar-Salinas CA.
Almeda-Valdes P, et al.
Eur J Endocrinol. 2019 Feb 1;180(2):99-107. doi: 10.1530/EJE-18-0677.
Eur J Endocrinol. 2019.
PMID: 30475225